Rethinking tablet strength loss at high manufacturing speeds
New CMAC research reveals that tablet strength loss at high production speeds is due to increased lubricant distribution from faster feedframe paddle rotation, not compression speed. Using Huxley Bertram’s HB50 simulator, the team isolated variables and replicated industrial conditions.
Bridging the gap: How knowledge graphs are driving a new era for pharmaceutical manufacturing
The CMAC Data Lab is entering a transformative era in drug development and manufacturing. As part of CMAC’s commitment to innovation and research excellence, we’ve integrated cutting-edge Knowledge Graph software from Plvs Ultra into our research facility.
Lonza joins CMAC to enhance service offering
Lonza has joined CMAC as a Translation to Industry Collaborator to enhance its service offering for specialty and enhanced drug product and particle technologies
CMAC welcomes John Mack as Tier 2 Industry Board representative
CMAC has appointed John Mack as a new member of its Industry Board. Representing CMAC’s Tier 2 membership, John’s role will enhance the Tier 2 community's connection to CMAC’s activities, ensuring the centre stays at the forefront of manufacturing advancements and continues to meet the evolving needs of its members.
Building trust: Engaging communities in the future of digital medicines manufacturing
At DM2, we recognize the vital role of public trust in the integration of digital technologies in medicine manufacturing. Through our outreach efforts we engaged a local community, gathering insights and addressing concerns about AI and robotics in healthcare. By fostering open dialogue, we aim to shift perceptions, paving the way for a brighter future in medicine.
Leading global CDMO Ajinomoto Bio-Pharma Services joins CMAC as new Translation to Industry Collaborator.
Global CDMO Ajinomoto Bio-Pharma Services has become the first organisation to position itself as a Translation to Industry Collaborator within CMAC, a world-leading centre for medicines manufacturing at the University of Strathclyde.
CMAC ignites global research ambitions: Hosting Postdoctoral researchers for their prestigious Marie Skłodowska-Curie Actions Postdoctoral Fellowship
CMAC launches campaign encouraging postdoctoral researchers from around the globe, to apply for a prestigious Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.
CMAC’s New EPSRC MediForge Hub to Build Industry 5.0 Solutions to Transform the Sustainable Development and Manufacturing of Medicines
The EPSRC MediForge Hub will transform the development and manufacturing of medicines by pioneering an Industry 5.0 manufacturing system for sustainable, resilient, and human-centric medicine production.
Revolutionising Nanoparticle Production: Technical Evaluation Introduces Cutting-Edge Formulation Technology
In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, leon-nanodrugs GmbH (LEON), has proudly announced a pioneering technical evaluation by CMAC, University of Strathclyde.
CMAC’s new CEDAR EPSRC CDT to train 90 PhDs in Cyber-Physical Systems For Medicines Manufacturing
This ground-breaking CDT is set to revolutionise the pharmaceutical and technology sectors by addressing critical skills needs within the industry.
CMAC Data Lab: A Digital Medicine Manufacturing Research Accelerator
The University of Strathclyde’s Continuous Manufacturing and Advanced Crystallisation (CMAC) are delighted to announce a new £11 million award from UK Research Partnership Investment Fund (UKRPIF) to deliver the CMAC Data Lab: A Digital Medicine Manufacturing Research Accelerator.
Meet our Team: Morell Kerr
In continuation of our monthly “Meet our Team” post, we are celebrating CMAC’s Operational Coordinator and PA To the Directors, Morell Kerr.
Meet our Team: Peter Hou
In our first Meet our Team post, we are celebrating CMAC's PhD student Peter Hou, who began working with CMAC in 2019.